Trials / Conditions / Leukaemia, Lymphocytic, Chronic

Leukaemia, Lymphocytic, Chronic

11 registered clinical trials studyying Leukaemia, Lymphocytic, Chronic.

Status	Trial	Sponsor	Phase
Completed	A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients W NCT01563055	GlaxoSmithKline	Phase 2
Completed	Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) NCT01520922	Novartis Pharmaceuticals	Phase 2
Completed	Phase IV Observational Study in Chronic Lymphocytic Leukemia NCT01453062	GlaxoSmithKline	—
Completed	Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects NCT01110031	GlaxoSmithKline	Phase 1
Terminated	Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy NCT01039376	Novartis Pharmaceuticals	Phase 3
Completed	A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Ch NCT01077622	GlaxoSmithKline	Phase 2
Completed	Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subje NCT00824265	Novartis Pharmaceuticals	Phase 3
Completed	Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lympho NCT00802737	GlaxoSmithKline	Phase 4
Terminated	Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocyti NCT00748189	Novartis Pharmaceuticals	Phase 3
Completed	Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients NCT00410163	GlaxoSmithKline	Phase 2
Completed	HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab NCT00349349	GlaxoSmithKline	Phase 2